0N6Z Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.00 |
| 52 Week High | €42.60 |
| 52 Week Low | €41.00 |
| Beta | 0.24 |
| 11 Month Change | -2.38% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -5.20% |
| 5 Year Change | n/a |
| Change since IPO | 174.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N6Z | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | n/a | -20.1% | 6.6% |
Return vs Industry: Insufficient data to determine how 0N6Z performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0N6Z performed against the UK Market.
Price Volatility
| 0N6Z volatility | |
|---|---|
| 0N6Z Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0N6Z's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0N6Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,464 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| 0N6Z fundamental statistics | |
|---|---|
| Market cap | €1.37b |
| Earnings (TTM) | €68.50m |
| Revenue (TTM) | €707.00m |
15.9x
P/E Ratio1.5x
P/S RatioIs 0N6Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N6Z income statement (TTM) | |
|---|---|
| Revenue | €707.00m |
| Cost of Revenue | €459.30m |
| Gross Profit | €247.70m |
| Other Expenses | €179.20m |
| Earnings | €68.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.73 |
| Gross Margin | 35.04% |
| Net Profit Margin | 9.69% |
| Debt/Equity Ratio | 116.4% |
How did 0N6Z perform over the long term?
See historical performance and comparison